Jang Yingping, Zhang Xiaoya, Zhu Rongxue, Li Songlin, Sun Shiyu, Li Wenqiang, Liu Hao
Department of Rehabilitation Medicine, Guangdong Second Provincial General Hospital, Guangzhou, China.
Engineering Technology Research Center for Sports Assistive Devices of Guangdong, Guangzhou Sport University, Guangzhou, China.
Front Microbiol. 2022 May 20;13:891144. doi: 10.3389/fmicb.2022.891144. eCollection 2022.
We report the biosynthesis of silver (Ag) nanoparticles (NAPs) (LEVB-Ag NAPs) by an environmentally friendly green synthesis approach using the phytoconstituents of leaf extract. The spectroscopic techniques were employed to characterize biosynthesized LEVB-Ag NAPs successfully. Biosynthesized LEVB-Ag NAPs were assessed for antibacterial and antimycotic activities against bacterium and mycological strains () using the serial dilution method. They were also evaluated for their biofilm inhibiting potential against both bacterial and fungi species. They were further assessed for the cytobiocompatible potential with two normal cell lines (293T and hMSC). The results demonstrate that the biosynthesized LEVB-Ag NAPs showed superior log reduction in bacterial and fungal growth and presented more than 99.50% killing efficiency. Moreover, biosynthesized LEVB-Ag NAPs excellently inhibited the biofilm formation of bacterial (Gram-positive and Gram-negative) and mycological strains and presented more than 80% biofilm inhibiting percentage compared to both plant extract and CHE-Ag NAPs. They further presented good cytobiocompatibility with 293T and hMSC cells compared to CHE-Ag NAPs. Biosynthesized LEVB-Ag NAPs presented superior antibacterial, antimycotic, biofilm inhibition, and cytobiocompatible results that might be attributed to the synergistic effect of the NAPs' physiochemical properties and the immobilized phytoconstituents from plant leaf extract on their surface. Hence, biosynthesized LEVB-Ag NAPs may be a promising contender for a variety of therapeutic applications.
我们报道了通过使用叶提取物的植物成分，采用环境友好的绿色合成方法生物合成银（Ag）纳米颗粒（NAPs）（LEVB-Ag NAPs）。采用光谱技术成功地表征了生物合成的LEVB-Ag NAPs。使用系列稀释法评估了生物合成的LEVB-Ag NAPs对细菌和真菌菌株的抗菌和抗真菌活性。还评估了它们对细菌和真菌物种的生物膜抑制潜力。进一步评估了它们与两种正常细胞系（293T和hMSC）的细胞生物相容性潜力。结果表明，生物合成的LEVB-Ag NAPs在细菌和真菌生长方面表现出优异的对数减少，并呈现出超过99.50%的杀灭效率。此外，与植物提取物和CHE-Ag NAPs相比，生物合成的LEVB-Ag NAPs出色地抑制了细菌（革兰氏阳性和革兰氏阴性）和真菌菌株的生物膜形成，并呈现出超过80%的生物膜抑制率。与CHE-Ag NAPs相比，它们与293T和hMSC细胞还具有良好的细胞生物相容性。生物合成的LEVB-Ag NAPs呈现出优异的抗菌、抗真菌、生物膜抑制和细胞生物相容性结果，这可能归因于NAPs的物理化学性质与固定在其表面的植物叶提取物中的植物成分的协同作用。因此，生物合成的LEVB-Ag NAPs可能是各种治疗应用的有前途的竞争者。
